Volume 1, Issue 2 , Pages e93-e102, December 2010
Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma
To access this article, please choose from the options below
This work was supported by Merck & Co., Kenilworth, New Jersey.
Prakash Navaratnam is a paid consultant for Merck & Co.; Eduardo Urdaneta was an employee of Merck & Co. (then Schering-Plough Corporation) when this study was conducted; John McLaughlin is a paid consultant for Merck & Co and is employed as a research scientist at Informagenics, LLC; Howard S. Friedman is the owner of Analytic Consulting, LLC, which performs consulting work in the pharmaceutical industry, including Merck & Co.
PII: S1877-1319(10)00011-X
doi:10.1016/j.ehrm.2010.08.001
© 2010 Elsevier Inc. All rights reserved.
Volume 1, Issue 2 , Pages e93-e102, December 2010
